Published on : Aug 19, 2014
HUYA Bioscience International, a China-based pharma company, has partnered with the Changzhou Center for Biotech Development (CZCBD) to accelerate biopharma innovations. The partnership will essentially focus on globally promoting innovative breakthroughs made by companies from Changzhou. The companies hope to specialize in meeting critical pipeline pharmaceutical needs at the global level.
Having recognized China’s capabilities to address the growing need for new compounds at the clinical and pre-clinical stage, the company’s emphasis now lies on creating value and advancing the development of biopharma compounds from China.
Toward this end, HUYA has also partnered and collaborated with numerous research establishments and universities across China. It has also been a pioneer in in-licensing compounds at both, the clinical stage and preclinical stage, from China.
CZCBD, the latest initiative, will function as an institutional unit entirely funded and supervised under the aegis of the Changzhou Science and Technology Bureau. This also makes it the first biotech development center that will operate under the supervision of the local government.
The partnership will remain dedicated to the establishment of a complete innovation system focusing on biopharma, and will aim to promote the output of over 800 pharma and biotech industries located in the region.
Companies located in the Changzhou region represent diverse fields including but not limited to: chemical drugs, biopharmaceuticals, equipment, consumables, medical devices, bioagriculture, as well as traditional Chinese medicine.